III-01 Stefanie Kraff Excel®-Based Tools for Pharmacokinetically Guided Dose Adjustment of Paclitaxel and Docetaxel Thursday 10:05-11:35 |
III-02 Andreas Krause Modeling the two peak phenomenon in pharmacokinetics using a gut passage model with two absorption sites Thursday 10:05-11:35 |
III-03 Elke Krekels Item response theory for the analysis of the placebo effect in Phase 3 studies of schizophrenia Thursday 10:05-11:35 |
III-04 Anders Kristoffersson Inter Occasion Variability (IOV) in Individual Optimal Design (OD) Thursday 10:05-11:35 |
III-05 Cédric Laouenan Modelling early viral hepatitis C kinetics in compensated cirrhotic treatment-experienced patients treated with triple therapy including telaprevir or boceprevir Thursday 10:05-11:35 |
III-06 Anna Largajolli An integrated glucose-insulin minimal model for IVGTT Thursday 10:05-11:35 |
III-07 Robert Leary A Fast Bootstrap Method Using EM Posteriors Thursday 10:05-11:35 |
III-08 Donghwan Lee Development of a Disease Progression Model in Korean Patients with Type 2 Diabetes Mellitus(T2DM) Thursday 10:05-11:35 |
III-09 Joomi Lee Population pharmacokinetics of prothionamide in Korean tuberculosis patients Thursday 10:05-11:35 |
III-10 Junghoon Lee Modeling Targeted Therapies in Oncology: Incorporation of Cell-cycle into a Tumor Growth Inhibition Model Thursday 10:05-11:35 |
III-11 Tarek Leil PK-PD Modeling using 4β-Hydroxycholesterol to Predict CYP3A Mediated Drug Interactions Thursday 10:05-11:35 |
III-12 Annabelle Lemenuel Diot How to improve the prediction of Sustained Virologic Response (SVR) for Hepatitis C patients using early Viral Load (VL) Information Thursday 10:05-11:35 |
III-13 Joanna Lewis A homeostatic model for CD4 count recovery in HIV-infected children Thursday 10:05-11:35 |
III-14 Yan Li Modeling and Simulation to Probe the Likely Difference in Pharmacokinetic Disposition of R- and S-Enantiomers Justifying the Development of Racemate Pomalidomide Thursday 10:05-11:35 |
III-15 Lia Liefaard Predicting levels of pharmacological response in long-term patient trials based on short-term dosing PK and biomarker data from healthy subjects Thursday 10:05-11:35 |
III-16 Karl-Heinz Liesenfeld Pharmacometric Characterization of the Elimination of Dabigatran by Haemodialysis Thursday 10:05-11:35 |
III-17 Otilia Lillin Model-based QTc interval risk assessment in Phase 1 studies and its impact on the drug development trajectory Thursday 10:05-11:35 |
III-18 Hyeong-Seok Lim Pharmacokinetics of S-1, an Oral 5-Fluorouracil Agent in Patients with Gastric Surgery Thursday 10:05-11:35 |
III-19 Andreas Lindauer Comparison of NONMEM Estimation Methods in the Application of a Markov-Model for Analyzing Sleep Data Thursday 10:05-11:35 |
III-20 Jesmin Lohy Das Simulations to investigate new Intermittent Preventive Therapy Dosing Regimens for Dihydroartemisinin-Piperaquine Thursday 10:05-11:35 |
III-21 Dan Lu Semi-mechanistic Multiple-analyte Population Model of Antibody-drug-conjugate Pharmacokinetics Thursday 10:05-11:35 |
III-22 Viera Lukacova Physiologically Based Pharmacokinetic (PBPK) Modeling of Amoxicillin in Neonates and Infants Thursday 10:05-11:35 |
III-23 Panos Macheras On the Properties of a Two-Stage Design for Bioequivalence Studies Thursday 10:05-11:35 |
III-24 Merran Macpherson Using modelling and simulation to evaluate potential drug repositioning to a new therapy area Thursday 10:05-11:35 |
III-25 Paolo Magni A PK-PD model of tumor growth after administration of an anti-angiogenic agent given alone or in combination therapies in xenograft mice Thursday 10:05-11:35 |
III-26 Mathilde Marchand Population Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Daratumumab in Multiple Myeloma Patients Thursday 10:05-11:35 |
III-27 Eleonora Marostica Population Pharmacokinetic Model of Ibrutinib, a BTK Inhibitor for the Treatment of B-cell malignancies Thursday 10:05-11:35 |
III-28 Hafedh Marouani Dosage regimen individualization of the once-daily amikacin treatment by using kinetics nomograms. Thursday 10:05-11:35 |
III-29 Amelie Marsot Population pharmacokinetics of baclofen in alcohol dependent patients Thursday 10:05-11:35 |
III-30 María Isabel Mas Fuster Stochastic Simulations Assist to Select the Intravenous Digoxin Dosing Protocol in Elderly Patients in Acute Atrial Fibrillation Thursday 10:05-11:35 |
III-31 Pauline Mazzocco Modeling tumor dynamics and overall survival in patients with low-grade gliomas treated with temozolomide. Thursday 10:05-11:35 |
III-32 Litaty Céphanoée Mbatchi A PK-PGx study of irinotecan: influence of genetic polymorphisms of xenoreceptors CAR (NR1I3) and PXR (NR1I2) on PK parameters Thursday 10:05-11:35 |
III-33 Sarah McLeay Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastro-esophageal reflux disease in children aged 1-11 years Thursday 10:05-11:35 |
III-34 Christophe Meille Modeling of Erlotinib Effect on Cell Growth Measured by in vitro Impedance-based Real-Time Cell Analysis Thursday 10:05-11:35 |
III-35 Olesya Melnichenko Characterizing the dose-efficacy relationship for anti-cancer drugs using longitudinal solid tumor modeling Thursday 10:05-11:35 |
III-36 Enrica Mezzalana A Target-Mediated Drug Disposition model integrated with a T lymphocyte pharmacodynamic model for Otelixizumab. Thursday 10:05-11:35 |
III-37 Iris Minichmayr A Microdialysate-based Integrated Model with Nonlinear Elimination for Determining Plasma and Tissue Pharmacokinetics of Linezolid in Four Distinct Populations Thursday 10:05-11:35 |
III-38 Jonathan Mochel Chronobiology of the Renin-Angiotensin-Aldosterone System (RAAS) in Dogs: Relation to Blood Pressure and Renal Physiology Thursday 10:05-11:35 |
III-39 Dirk Jan Moes Evaluating the effect of CYP3A4 and CYP3A5 polymorphisms on cyclosporine, everolimus and tacrolimus pharmacokinetics in renal transplantation patients. Thursday 10:05-11:35 |
III-40 John Mondick Mixed Effects Modeling to Quantify the Effect of Empagliflozin Exposure on the Renal Glucose Threshold in Patients with Type 2 Diabetes Mellitus Thursday 10:05-11:35 |
III-41 Morris Muliaditan Model-based evaluation of iron overload in patients affected by transfusion dependent diseases Thursday 10:05-11:35 |
III-42 Flora Musuamba-Tshinanu Modelling of disease progression and drug effects in preclinical models of neuropathic pain Thursday 10:05-11:35 |
III-43 Kiyohiko Nakai Urinary C-terminal Telopeptide of Type-I Collagen Concentration (uCTx) as a Possible Biomarker for Osteoporosis Treatment; A Direct Comparison of the Modeling and Simulation (M&S) Data and those Actually Obtained in Japanese Patients with Osteoporosis Following a Three-year-treatment with Ibandronic Acid (IBN) Thursday 10:05-11:35 |
III-44 Thu Thuy Nguyen Mechanistic Model to Characterize and Predict Fecal Excretion of Ciprofloxacin Resistant Enterobacteria with Various Dosage Regimens Thursday 10:05-11:35 |
III-45 Tram Nguyen Influence of a priori information, designs and undetectable data on individual parameters estimation and prediction of hepatitis C treatment outcome Thursday 10:05-11:35 |
III-46 Xavier Nicolas Steady-state achievement and accumulation for a compound with bi-phasic disposition and long terminal half-life, estimation by different techniques Thursday 10:05-11:35 |
III-47 Ronald Niebecker Are datasets for NLME models large enough for a bootstrap to provide reliable parameter uncertainty distributions? Thursday 10:05-11:35 |
III-48 Lisa O'Brien Implementation of a Global NONMEM Modeling Environment Thursday 10:05-11:35 |
III-49 Kayode Ogungbenro A physiological based pharmacokinetic model for low dose methotrexate in humans Thursday 10:05-11:35 |
III-50 Jaeseong Oh A Population Pharmacokinetic-Pharmacodynamic Analysis of Fimasartan in Patients with Mild to Moderate Essential Hypertension Thursday 10:05-11:35 |
III-51 Fredrik Öhrn Longitudinal Modelling of FEV1 Effect of Bronchodilators Thursday 10:05-11:35 |
III-52 Andrés Olivares-Morales Qualitative prediction of human oral bioavailability from animal oral bioavailability data employing ROC analysis Thursday 10:05-11:35 |
III-53 Erik Olofsen Simultaneous stochastic modeling of pharmacokinetic and pharmacodynamic data with noncoinciding sampling times Thursday 10:05-11:35 |
III-54 Sean Oosterholt PKPD modelling of PGE2 inhibition and dose selection of a novel COX-2 inhibitor in humans. Thursday 10:05-11:35 |
III-55 Ignacio Ortega Application of allometric techniques to predict F10503LO1 PK parameters in human Thursday 10:05-11:35 |
III-56 Jeongki Paek Population pharmacokinetic model of sildenafil describing first-pass effect to its metabolite Thursday 10:05-11:35 |
III-57 Sung Min Park Population pharmacokinetic/pharmacodynamic modeling for transformed binary effect data of triflusal in healthy Korean male volunteers Thursday 10:05-11:35 |
III-58 Zinnia Parra-Guillen Population semi-mechanistic modelling of tumour response elicited by Immune-stimulatory based therapeutics in mice Thursday 10:05-11:35 |
III-59 Ines Paule Population pharmacokinetics of an experimental drug’s oral modified release formulation in healthy volunteers, quantification of sensitivity to types and timings of meals. Thursday 10:05-11:35 |
III-60 Sophie Peigné Paediatric Pharmacokinetic methodologies: Evaluation and comparison Thursday 10:05-11:35 |
III-61 Nathalie Perdaems A semi-mechanistic PBPK model to predict blood, cerebrospinal fluid and brain concentrations of a compound in mouse, rat, monkey and human. Thursday 10:05-11:35 |
III-62 Chiara Piana Optimal sampling and model-based dosing algorithm for busulfan in bone marrow transplantation patients. Thursday 10:05-11:35 |
III-63 Sebastian Polak Pharmacokinetic (PK) and pharmacodynamic (PD) implications of diurnal variation of gastric emptying and small intestinal transit time for quinidine: A mechanistic simulation. Thursday 10:05-11:35 |
III-64 Angelica Quartino Evaluation of Tumor Size Metrics to Predict Survival in Advanced Gastric Cancer Thursday 10:05-11:35 |